Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 865-873

  Gomes, Marisa Z R ^a,b   Mulanovich, Victor E ^a   Jiang, Y ^a   Lewis, Russell E ^a,c   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLUS; AUDITORY HALLUCINATION; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HUMAN; INVASIVE ASPERGILLOSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOULD; NEUROTOXICITY; PRIMARY ANTIFUNGAL PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; REMISSION; SYSTEMIC MYCOSIS; TERTIARY CARE CENTER; THORAX PAIN; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ECHINOCANDINS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TERTIARY CARE CENTERS; TRIAZOLES;

EID: 84893448431     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01525-13     Document Type: Article

References (44)

1. Kontoyiannis DP. 2012. Invasive mycoses: strategies for effective management. Am. J. Med. 125:S25-S38. http://dx.doi.org/10.1016/j.amjmed.2011.10. 009.
2. Lewis RE. 2012. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. Am. J. Ther. 19:51-63. http://dx.doi.org/10.1097/MJT.0b013e3181ff7e10.
3. Kontoyiannis DP. 2011. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant. 46:165-173. http://dx.doi.org/10.1038/bmt.2010.256.
4. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A. 2006. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91: 1068-1075. http://www.haematologica.org/content/91/8/1068.long.
5. Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT, Nosari A, Candoni A, Bonini A, Mattei D, de Waure C, Fianchi L, Valentini CG, Aversa F, Leone G, Pagano L. 2008. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur. J. Haematol. 81:242-243. http://dx.doi.org/10.1111/j.1600-0609.2008.01096.x.
6. Vehreschild JJ, Ruping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA. 2010. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J. Antimicrob. Chemother. 65:1466-1471. http://dx.doi.org/10.1093/jac/dkq121.
7. Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Matturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foa R, Micozzi A. 2012. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, reallife experience. Haematologica 97:560-567. http://dx.doi.org/10.3324/haematol.2011.053058.
8. Hahn J, Stifel F, Reichle A, Holler E, Andreesen R. 2011. Clinical experience with posaconazole prophylaxis-a retrospective analysis in a haematological unit. Mycoses 54(Suppl 1):12-16. http://dx.doi.org/10.1111/j. 1439-0507.2010.01980.x.
9. Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D. 2012. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J. Antimicrob. Chemother. 67: 2268-2273. http://dx.doi.org/10.1093/jac/dks189.
10. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA. 2012. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/ itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 97:459-463. http://dx.doi.org/10.3324/haematol.2011.051995.
11. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH. 2006. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother. 50:143-147. http://dx.doi.org/10.1128/AAC.50.1. 143-147.2006.
12. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094.
13. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. 2011. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19:19-26. http://dx.doi.org/10. 1007/s00520-009-0783-3.
14. Rogers TR, Slavin MA, Donnelly JP. 2011. Antifungal prophylaxis during treatmentforhaematologicalmalignancies: arewethere yet? Br. J.Haematol.153:681- 697. http://dx.doi.org/10.1111/j.1365-2141.2011.08650.x.
15. Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Kruger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ. 2009. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113-122. http://dx.doi.org/10. 3324/haematol.11665.
16. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy Infectious Diseases Mycoses Study Group Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821. http://dx.doi.org/10.1086/588660.
17. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, Gachot B, Heinz WJ, Lass-Florl C, Ribaud P, Thiebaut A, Cordonnier C. 2011. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. 46:709-718. http://dx.doi.org/10.1038/bmt.2010.175.
18. Slavin MA, Heath CH, Thursky KA, Morrissey CO, Szer J, Ling LM, Milliken ST, Grigg AP. 2008. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern. Med. J. 38:468-476. http://dx.doi.org/10. 1111/j.1445-5994.2008.01723.x.
19. Rogers TR, Morton CO, Springer J, Conneally E, Heinz W, Kenny C, Frost S, Einsele H, Loeffler J. 2013. Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. Br. J. Haematol. 161:517-524. http://dx.doi.org/10.1111/bjh.12285.
20. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191: 1350-1360. http://dx.doi.org/10.1086/428780.
21. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo Clin. Proc. 86:805-817. http://dx.doi.org/10.4065/mcp.2011.0247.
22. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. 2009. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745-4752. http://dx.doi.org/10.1002/cncr.24507.
23. Gomes MZ, Lewis RE, Kontoyiannis DP. 2011. Mucormycosis caused by unusual mucormycetes, non-Rhizopus,-Mucor, and-Lichtheimia species. Clin. Microbiol. Rev. 24:411-445. http://dx.doi.org/10.1128/CMR.00056-10.
24. Leventakos K, Lewis RE, Kontoyiannis DP. 2010. Fungal infections in leukemia patients: how do we prevent and treat them? Clin. Infect. Dis. 50:405-415. http://dx.doi.org/10.1086/649879.
25. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. 2008. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112:2309-2312. http://dx.doi.org/10.1002/cncr.23441.
26. Caira M, Mancinelli M, Leone G, Pagano L. 2011. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med. Mycol. 49(Suppl 1):S13-S16. http://dx.doi.org/10.3109/13693786.2010.509138.
27. Castagnola E, Haupt R. 2012. Empirical versus pre-emptive antifungal therapy for persistent febrile neutropenia. Haematologica 97:e1. http://dx.doi.org/10.3324/haematol.2011.056077.
28. Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR, Spelman T, Slavin MA. 2013. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect. Dis. 13:519-528. http://dx.doi.org/10.1016/S1473-3099(13)70076-8.
29. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. 2006. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91:986-989. http://www. haematologica.org/content/91/7/986.long.
30. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55:532-538. http://dx.doi.org/10.1128/AAC.01128-10.
31. Ben-Ami R, Kontoyiannis DP. 2012. Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on Candida albicans fitness and virulence. Virulence 3:95-97. http://dx.doi.org/10.4161/viru.3.1.18886.
32. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O, French Mycoses Study Group. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90. http://dx.doi.org/10.3201/eid1801.110556.
33. Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D. 2011. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob. Agents Chemother. 55:5358-5361. http://dx.doi.org/10.1128/AAC.00690- 11.
34. Pfeiffer CD, Fine JP, Safdar N. 2006. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42:1417-1427. http://dx.doi.org/10.1086/503427.
35. Cummings JR, Jamison GR, Boudreaux JW, Howles MJ, Walsh TJ, Hayden RT. 2007. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn. Microbiol. Infect. Dis. 59:113-115. http://dx.doi.org/10.1016/j.diagmicrobio.2007.04.022.
36. Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, Cascio GL. 2012. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay. J. Clin. Microbiol. 50:1051-1053. http://dx.doi.org/10.1128/JCM.05946-11.
37. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55:4465-4468. http://dx.doi.org/10.1128/AAC. 00185-11.
38. Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA. 2012. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int. J. Antimicrob. Agents 39:1-10. http://dx.doi.org/10.1016/j.ijantimicag.2011.07.013.
39. Ruping MJ, Muller C, Vehreschild JJ, Bohme A, Mousset S, Harnischmacher U, Frommolt P, Wassmer G, Drzisga I, Hallek M, Cornely OA. 2011. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. Mycoses 54:230-233. http://dx.doi.org/10.1111/j.1439-0507.2009.01803. x.
40. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. http://dx.doi.org/10.1016/S0140-6736(03)14472-8.
41. Marr KA, Laverdiere M, Gugel A, Leisenring W. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40:1762-1769. http://dx.doi.org/10.1086/429921.
42. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. 2009. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951. http://dx.doi.org/10.1182/blood-2009-03-209262.
43. Estey EH. 2012. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87:89-99. http://dx.doi.org/10. 1002/ajh.22246.
44. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176. http://dx.doi.org/10. 1016/j.drup.2011.01.004.